TheRapeutic StrAtegies for Obstructive SleeP Apnea in Older Adults with OverweigHt or Obesity: A RandomizEd Clinical TriaL (RAPHAEL study)

2025-524819-37-00 · tracked via the Priya Life Science EU tracker

Sponsor

Institut De Recerca Biomedica De Lleida Fundacio Dr. Pifarre

Sponsor type

Laboratory/Research/Testing facility

Therapeutic area

Respiratory Tract Diseases

Decision date

30/03/2026

Enrollment target

345

Sites

Spain

Condition studied

obstructive sleep apnea

Investigational medicinal product(s)

Wegovy 2.4 mg solution for injection in pre-filled pen

Eligibility

Age group

65+ years

Sex

Female, Male

Primary endpoint

The change in Apnea–Hypopnea Index (AHI) at 6 months

Endpoint detail

OSA pathophysiology (hypoxic burden, delta heart rate, loop gain)., Symptoms (daytime sleepiness)., Blood pressure., Functional and psychological domains (quality of life, sleep quality, circadian rest-activity rhythm, cognitive function, mental health)., Body weight., Molecular mechanisms (biomarkers of inflammation, oxidative stress, obesity, and cardiovascular risk)., Cost-effectiveness.

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-524819-37-00 on CTIS ↗ ← All trials in the EU